Intapp: Caution On This Cloud Player
Intapp has gone public, but the price performance of its stock has been uninspiring. Here’s my full investment analysis.
recent post
-
Aug 21 2025 -
Aug 21 2025
-
Aug 21 2025
-
Aug 21 2025
-
Lebanon medicine importers warn foreign drugs running out
Lebanon’s medicine importers Sunday said they had run out of hundreds of essential drugs and warned of more shortages,
China Regulator Orders Didi to Be Removed From App Stores
(Bloomberg) — China’s cyberspace regulator ordered app stores to remove Didi Chuxing from their list of offerings, citing serious…
Coupa: I’m Finally Nibbling On This Stock
Click to read why I view the opportunity to buy Coupa Software at ~30% off highs as a well-timed
The ‘Sunday Effect’ Sends Crypto Crashing on Weekends – Which Means It Might Never Go Mainstream
Ever heard of the “Sunday effect”? Lately, it seems every weekend, crypto values plummet – and it’s a trend
Road to Retirement: Crypto millionaires, are you missing out?
In a recent CNBC survey of millionaire millennials, nearly half of them reported having at least 25% of their
Is It Time to Buy the Dow Jones’ 3 Worst-Performing June Stocks?
A trio of names is suspiciously in the same boat for the same reason, perhaps dropping a hint too
Chipotle’s CEO Made a Bold Claim About Growth. Is It Time to Get Excited?
The popular Tex-Mex chain just got a boost from CEO Brian Niccol, but it still might not signal a
2 Reasons to Buy Intellia — and 1 Big Reason Why I Won’t
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock…
AbbVie: The Path To 30% Annual Returns
AbbVie has been over-punished for its looming loss of Humira. ABBV stock is way too cheap, and over time